var data={"title":"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/contributors\" class=\"contributor contributor_credentials\">Peter H Schur, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/contributors\" class=\"contributor contributor_credentials\">Daniel E Furst, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/contributors\" class=\"contributor contributor_credentials\">Paul L Romain, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 18, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the late 1990s, the success of biologic agents in the treatment of rheumatoid arthritis (RA) has dramatically altered the approach to treating this disease and a variety of other inflammatory illnesses. Four biologic approaches have achieved major impact in RA:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor necrosis factor (TNF)-alpha inhibition</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>B-cell depletion</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disruption of T-cell costimulation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interleukin (IL)-1 and IL-6 inhibition</p><p/><p>Major clinical trials of TNF inhibitors in RA will be reviewed here. General approaches to the therapy of RA and the major clinical trials of biologic agents other than TNF inhibitors and of non-biologic disease-modifying antirheumatic drugs (DMARDs) are presented elsewhere. (See <a href=\"topic.htm?path=general-principles-of-management-of-rheumatoid-arthritis-in-adults\" class=\"medical medical_review\">&quot;General principles of management of rheumatoid arthritis in adults&quot;</a> and <a href=\"topic.htm?path=rituximab-and-other-b-cell-targeted-therapies-for-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;Rituximab and other B cell targeted therapies for rheumatoid arthritis&quot;</a> and <a href=\"topic.htm?path=t-cell-targeted-therapies-for-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;T-cell targeted therapies for rheumatoid arthritis&quot;</a> and <a href=\"topic.htm?path=randomized-clinical-trials-in-rheumatoid-arthritis-of-biologic-agents-that-inhibit-il-1-il-6-and-rankl\" class=\"medical medical_review\">&quot;Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL&quot;</a> and <a href=\"topic.htm?path=randomized-clinical-trials-of-combinations-of-nonbiologic-dmards-in-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis&quot;</a>.)</p><p>All of the trials included in this review were randomized, double-blind, placebo-controlled investigations. The focus in this review is on the clinical trials that were instrumental in defining the clinical roles of these biologic agents. For each trial, the following features are described:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Trial name &ndash; Each trial is listed by its acronym, the title of the paper in which the primary results were published, or both.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; The duration of the trial, the number of patients studied, and the specific treatment groups are outlined.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; The entry criteria are summarized, and the type of background therapy permitted is indicated.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome measures &ndash; The outcome measures specified in advance by the investigators are listed.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcome measures &ndash; Other outcome measures essential to understanding the full impact of the intervention and the context of the trial are mentioned.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; The main efficacy results are reviewed. Important adverse effects are also mentioned.</p><p/><p>Unless otherwise specified, all of the trials outlined below permitted patients to continue to use their baseline nonsteroidal antiinflammatory agents and stable doses of up to 9 <span class=\"nowrap\">mg/day</span> of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Five inhibitors of tumor necrosis factor (TNF)-alpha are widely available for clinical use: <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a>, <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a>, <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a>, and <a href=\"topic.htm?path=certolizumab-pegol-drug-information\" class=\"drug drug_general\">certolizumab pegol</a>. All TNF inhibitors are more effective when employed with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> than when they are used as monotherapy [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>&ldquo;Biosimilar&rdquo; forms of <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> and <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> have also been developed. A &ldquo;biosimilar&rdquo; is defined by the World Health Organization (WHO) as a &ldquo;biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product&rdquo; [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/3\" class=\"abstract_t\">3</a>]; &ldquo;similarity&rdquo; is defined as the &ldquo;absence of a relevant difference in the parameter of interest.&rdquo; The biosimilar agents are expected to be marketed at a lower cost than the original biologic medications. (See <a href=\"#H7057834\" class=\"local\">'Infliximab biosimilar'</a> below and <a href=\"#H7065908\" class=\"local\">'Etanercept biosimilar'</a> below.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ETANERCEPT AND RELATED AGENTS</span></p><p class=\"headingAnchor\" id=\"H7065759\"><span class=\"h2\">Etanercept</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept</a> is a recombinant fusion protein that consists of the soluble tumor necrosis factor (TNF) receptor (p75) linked to the Fc portion of human immunoglobulin (Ig)G1 (TNFR:Fc). Etanercept is administered by subcutaneous injection once or twice weekly. A number of major randomized clinical trials in patients with rheumatoid arthritis (RA) and several systematic reviews and meta-analyses of etanercept have been conducted [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Trial name &mdash; Treatment of RA with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Three-month trial involving 180 patients, assigned to one of four treatment groups: either placebo or one of three doses of <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> twice weekly. The etanercept doses were 0.25, 2, or 16 <span class=\"nowrap\">mg/m<sup>2</sup></span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; RA patients refractory to at least one DMARD.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcomes &ndash; Changes in the number of swollen and tender joints between entry and the end of month three.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; The ACR20 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>), ACR50, and adverse events were the major secondary outcomes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept</a> was associated with significant, dose-related reductions in disease activity. Seventy-five percent of patients assigned to the highest etanercept dose achieved ACR20 responses, compared with 14 percent in the placebo group.</p><p/><p class=\"bulletIndent1\">The mean percent reduction in the number of tender or swollen joints was 61 percent, compared with 25 percent in the placebo group. No dose-limiting adverse effects were observed, and no patients developed antibodies to <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>.</p><p/><p>Trial name &mdash; <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept</a> therapy in RA: A randomized, controlled trial [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Six-month trial of <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> involving 234 patients, assigned to one of three treatment groups:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept</a> 25 mg twice weekly</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept</a> 10 mg twice weekly</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Placebo twice weekly</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; RA patients in ACR functional class I, II, or III [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/7\" class=\"abstract_t\">7</a>]. All patients had failed at least one but not more than four disease-modifying antirheumatic drugs (DMARDs). In addition, patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least 10 swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least 12 tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>An erythrocyte sedimentation rate &gt;27 <span class=\"nowrap\">mm/hour,</span> a serum C-reactive protein level &gt;1.9 <span class=\"nowrap\">mg/dL,</span> or at least 45 minutes of morning stiffness</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; ACR20 and ACR50 at three and six months (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR70 at three and six months, the number of swollen or tender joints, and quality of life.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept</a> significantly reduced disease activity and other outcome measures in a dose-related fashion at both three and six months. At six months, in the 25 mg, 10 mg, and placebo groups, an ACR20 response was achieved by 59, 51, and 11 percent of patients, respectively. An ACR50 response was achieved by 40, 24, and 5 percent of the three groups, respectively, and an ACR70 response was achieved by 15, 9, and 1 percent, respectively.</p><p/><p>Trial name &mdash; A trial of <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, a TNF receptor: Fc fusion protein in patients with RA receiving <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Twenty-four-week trial that involved 89 patients assigned either to receive <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> 25 mg twice weekly or to receive placebo added to MTX.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; The patients had persistently active RA despite stable MTX doses between 15 and 25 <span class=\"nowrap\">mg/week</span> for at least six months. In addition, the patients had active disease defined as swelling in at least six joints and tenderness in at least six joints.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; ACR20 at 24 weeks (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR20 at 12 weeks; ACR50 and ACR70 at 12 and 24 weeks.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; At 24 weeks, 71 percent of the patients receiving <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> plus MTX and 27 percent of those receiving placebo plus MTX achieved ACR20 responses. Thirty-nine percent of patients receiving etanercept plus MTX versus 3 percent of those receiving placebo plus MTX met the ACR50 criteria at that time point. Patients receiving etanercept plus MTX had significantly better outcomes according to all measures of disease activity.</p><p/><p>Trial name &mdash; A comparison of <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> and MTX in patients with early RA [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Twelve-month trial of 632 patients with &ldquo;early RA&rdquo; (defined below), treated either with twice-weekly subcutaneous <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> (10 or 25 mg) or with weekly oral MTX (mean, 19 mg per week) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/9\" class=\"abstract_t\">9</a>]. A study of longer follow-up provided data on these patients at two years [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; The patients had had RA for no more than three years and had never been treated with MTX. In addition, patients were required to have all of the following:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Rheumatoid factor positivity</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least three bone erosions evident on radiographs of hands, wrists, and feet</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least 10 swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least 12 tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>An erythrocyte sedimentation rate &gt;27 <span class=\"nowrap\">mm/hour,</span> a serum C-reactive protein level &gt;1.9 <span class=\"nowrap\">mg/dL,</span> or at least 45 minutes of morning stiffness</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; This trial used a new outcome measure for its primary outcome: the ACR-N [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/11\" class=\"abstract_t\">11</a>]. The ACR-N, which represents the overall response of each patient, was designated as the smallest degree of improvement from baseline in three criteria: the number of tender joints, the number of swollen joints, and the median of the five remaining measures of disease activity in the ACR response criteria (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>). A negative ACR-N indicates worsening of activity from baseline. (See <a href=\"topic.htm?path=assessment-of-rheumatoid-arthritis-activity-in-clinical-trials-and-clinical-practice#H7361109\" class=\"medical medical_review\">&quot;Assessment of rheumatoid arthritis activity in clinical trials and clinical practice&quot;, section on 'ACR response criteria'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; Percentages of patients with ACR20, ACR50, and ACR70 responses (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>). A primary radiologic endpoint was also identified: change in Sharp scores over a period of 12 months [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/7,12-14\" class=\"abstract_t\">7,12-14</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; Patients in the group assigned to receive 25 mg of <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> twice weekly had significantly greater areas under the curve for ACR-N at 3, 6, 9, and 12 months, indicating superior clinical responses. Patients treated with etanercept 25 mg group also had a more rapid rate of improvement and a higher likelihood of achieving ACR20, ACR50, and ACR70 responses than did those in the MTX group. The 10 mg etanercept dose was not superior to MTX in most outcome measures.</p><p/><p class=\"bulletIndent1\">The mean increase in the erosion score during the first six months was 0.3 in the group assigned to receive 25 mg of <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> and 0.68 in the MTX group. The increases during the first 12 months were 0.47 and 1.03, respectively. Adverse events, including infections, were also fewer in the 25 mg etanercept group.</p><p/><p class=\"bulletIndent1\">Data from the two-year follow-up study indicated that <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> as monotherapy was superior to MTX in the reduction of disease activity, in the arrest of structural damage, and in the prevention of disability.</p><p/><p>Trial name &mdash; Comparison of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> monotherapy with a combination of methotrexate and <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> in active, early, moderate to severe rheumatoid arthritis (COMET) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Twelve-month trial of 542 patients with early moderate to severe RA, treated either with oral <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> alone (titrated from 7.5 to a maximum of 20 <span class=\"nowrap\">mg/week,</span> mean 19.6 mg) or with MTX (same titration, mean 16.8 <span class=\"nowrap\">mg/week)</span> plus subcutaneous <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> (50 <span class=\"nowrap\">mg/week)</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; The patients were 18 years of age or older and had not been previously treated with MTX, <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, or another TNF antagonist; or had not been treated in the four weeks before baseline visits with either glucocorticoid injections or other DMARDs. In addition, patients met the following criteria:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Disease duration of 3 to 24 months</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Disease activity score in 28 joints (DAS28) of 3.2 or greater (mean 6.5) (see <a href=\"topic.htm?path=assessment-of-rheumatoid-arthritis-activity-in-clinical-trials-and-clinical-practice#H7361046\" class=\"medical medical_review\">&quot;Assessment of rheumatoid arthritis activity in clinical trials and clinical practice&quot;, section on 'DAS28 score'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>ESR &ge;28 <span class=\"nowrap\">mm/hour</span> or CRP &ge;20 <span class=\"nowrap\">mg/L</span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcomes &ndash; Proportion of patients achieving remission (DAS28 &lt;2.6) at week 52 and the change in van der Heijde modified total Sharp score (mTSS: joint erosion score plus joint space narrowing score) from baseline to week 52 [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/14,16-18\" class=\"abstract_t\">14,16-18</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; Proportion of patients achieving DAS44 remission (DAS44 &lt;1.6), ACR20, ACR50, and ACR70 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>); functional status (health assessment questionnaire disability index); and employment status (stopping working during the study). (See <a href=\"topic.htm?path=assessment-of-rheumatoid-arthritis-activity-in-clinical-trials-and-clinical-practice#H7361081\" class=\"medical medical_review\">&quot;Assessment of rheumatoid arthritis activity in clinical trials and clinical practice&quot;, section on 'Health Assessment Questionnaire (HAQ)'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; At one year of treatment, remission was achieved significantly more often in patients receiving the combination of <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> and MTX (50 versus 28 percent with MTX alone). In addition, radiographic non-progression was significantly more frequent with combination therapy (80 versus 59 percent). The frequency of serious adverse events, 12 percent overall, was comparable in the two groups.</p><p/><p class=\"headingAnchor\" id=\"H7065908\"><span class=\"h2\">Etanercept biosimilar</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>SB4 is a biosimilar to <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, produced by recombinant DNA technology. SB4 has been shown to exhibit similar structural, physiochemical, and biologic properties, and therapeutic equivalence to the etanercept reference molecule using a variety of analytic methods, although SB4 and etanercept do differ by a single amino acid [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/19\" class=\"abstract_t\">19</a>]. The clinical benefit and safety of SB4 were evaluated in a randomized trial involving 596 patients with active RA despite MTX therapy, in whom the addition of SB4 resulted in an equivalent frequency of ACR20, ACR50, and ACR70 responses at week 24 compared with the reference agent, etanercept [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/19\" class=\"abstract_t\">19</a>]. The incidence of adverse events related to treatment was also comparable, and both drugs were well-tolerated, while the frequency of antidrug antibodies was significantly lower with the biosimilar, SB4 (0.7 versus 13.1 percent).</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">INFLIXIMAB AND RELATED AGENTS</span></p><p class=\"headingAnchor\" id=\"H7057828\"><span class=\"h2\">Infliximab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> is a chimeric <span class=\"nowrap\">(human/murine)</span> immunoglobulin (Ig)G1 monoclonal antibody directed against tumor necrosis factor (TNF). Infliximab is administered via intravenous infusion, typically at intervals of six to eight weeks following two doses separated by two weeks.</p><p>Several major clinical trials of <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> have been performed [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/20-23\" class=\"abstract_t\">20-23</a>]. Two trials summarize the clinical evidence for the efficacy of infliximab in rheumatoid arthritis (RA) well [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/20,23\" class=\"abstract_t\">20,23</a>].</p><p>Trial name &mdash; <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> and MTX in the treatment of RA [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Fifty-four week study of 428 patients randomized into five treatment groups:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Placebo plus <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) (n = 88)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> 3 <span class=\"nowrap\">mg/kg</span> every eight weeks plus MTX (n = 86)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> 3 <span class=\"nowrap\">mg/kg</span> every four weeks plus MTX (n = 86)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> 10 <span class=\"nowrap\">mg/kg</span> every eight weeks plus MTX (n = 87)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> 10 <span class=\"nowrap\">mg/kg</span> every four weeks plus MTX (n = 81)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with active RA despite at least 12.5 mg of <span class=\"nowrap\">MTX/week</span>. Active RA was defined as:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least six swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least six tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least two of the following: an erythrocyte sedimentation rate &gt; 27 <span class=\"nowrap\">mm/hour,</span> a serum C-reactive protein level &gt;1.9 <span class=\"nowrap\">mg/dL,</span> or at least 45 minutes of morning stiffness</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; ACR20 response (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR50 and ACR70 responses and the Health Assessment Questionnaire (HAQ) score [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/24\" class=\"abstract_t\">24</a>]. The effect of therapy on articular damage was assessed on the basis of the van der Heijde modification of the Sharp scoring system [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/14,16-18\" class=\"abstract_t\">14,16-18</a>], using radiographs of the hands and feet.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; The combination of <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> and MTX was tolerated well and resulted in clinical responses in 52 percent of patients treated with both infliximab and MTX, compared with 17 percent of those treated with MTX alone. The symptoms and signs of RA decreased more in all of the infliximab groups as judged by ACR20, ACR50, and ACR70 responses compared with the group that received MTX alone.</p><p/><p class=\"bulletIndent1\">The improvement in HAQ scores was also significantly better with <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> plus MTX than with MTX alone. Radiographic evidence of joint damage increased in the group given MTX but not in the groups given infliximab and MTX (mean change in radiographic score, 7 versus 0.6).</p><p/><p>Trial name &mdash; Combination of <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> and MTX therapy for early RA (Active-Controlled Study of Patients Receiving Infliximab for the Treatment of RA of Early Onset, ASPIRE) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Fifty-four-week trial involving 1049 patients randomized into three different treatment groups:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Placebo plus MTX (20 <span class=\"nowrap\">mg/week)</span> (n = 298)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> 3 <span class=\"nowrap\">mg/kg</span> every eight weeks plus MTX (n = 373)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> 6 <span class=\"nowrap\">mg/kg</span> every four weeks plus MTX (n = 378)</p><p/><p>Investigational infusions were administered at weeks zero, two, and six, and then every eight weeks through week 46.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with RA for longer than three months but less than three years who had never been treated with MTX. All patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least 10 swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least 12 tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>One or more of the following: rheumatoid factor positivity, radiographic erosions of the hands or feet, or a serum C-reactive protein level &gt;1.9 <span class=\"nowrap\">mg/dL</span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; The percentage of ACR improvement (ACR-N) from baseline to week 54 [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/9,11\" class=\"abstract_t\">9,11</a>]. As noted above, the ACR-N is defined as the minimum of the following three items:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The percentage change from baseline in the number of tender joints</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The percentage change from baseline in the number of swollen joints</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The median of the percentage change from baseline for the patient&rsquo;s global assessment, clinician&rsquo;s global assessment, pain, disability, and serum levels of C-reactive protein</p><p/><p>A negative ACR-N indicates worsening of activity from baseline.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR20 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>), ACR50, ACR70, ACR90, HAQ score [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/24,25\" class=\"abstract_t\">24,25</a>], and the Disease Activity Score in 28 joints (DAS28) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/26,27\" class=\"abstract_t\">26,27</a>]. (See <a href=\"topic.htm?path=assessment-of-rheumatoid-arthritis-activity-in-clinical-trials-and-clinical-practice#H7361046\" class=\"medical medical_review\">&quot;Assessment of rheumatoid arthritis activity in clinical trials and clinical practice&quot;, section on 'DAS28 score'</a>.)</p><p/><p class=\"bulletIndent1\">A major clinical response was defined as an ACR70 for six consecutive months.</p><p/><p class=\"bulletIndent1\">Radiologic outcomes were assessed using the van der Heijde modification of the total Sharp score [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; The median percentage improvement in ACR-N was higher in the 6 <span class=\"nowrap\">mg/kg</span> and 3 <span class=\"nowrap\">mg/kg</span> <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> groups compared with the MTX alone group (47 versus 39 versus 26 percent, respectively). However, only 17 percent, 12 percent, and 8 percent of patients in the three groups, respectively, achieved ACR70 responses for six consecutive months.</p><p/><p class=\"bulletIndent1\">Patients in the 6 <span class=\"nowrap\">mg/kg</span> and 3 <span class=\"nowrap\">mg/kg</span> <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> groups also showed less radiographic progression, measured by change in total Sharp score, than those receiving MTX alone: 0.4 <span class=\"nowrap\">+/-</span> 5.8 and 0.5 <span class=\"nowrap\">+/-</span> 5.6 versus 3.7 <span class=\"nowrap\">+/-</span> 9.6, respectively. This difference could not be attributed entirely to greater reduction in disease activity, as less radiographic worsening was seen with infliximab treatment at each level of disease activity [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/28\" class=\"abstract_t\">28</a>].</p><p/><p class=\"bulletIndent1\">Physical function as measured by the HAQ score improved significantly more in the MTX 3 <span class=\"nowrap\">mg/kg</span> <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> and in the MTX 6 <span class=\"nowrap\">mg/kg</span> infliximab groups than in the MTX placebo group.</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> therapy was associated with a significantly higher incidence of serious adverse events (5 versus 2 percent) and serious infections (2 versus 0 percent), especially community-acquired pneumonia (19 versus 0 cases) and tuberculosis (four versus 0 cases).</p><p/><p class=\"headingAnchor\" id=\"H7057834\"><span class=\"h2\">Infliximab biosimilar</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The IgG1 chimeric human&ndash;murine monoclonal antibody, CT-P13 [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/29,30\" class=\"abstract_t\">29,30</a>], was developed as an anti-TNF alpha monoclonal antibody biosimilar to the original (termed &ldquo;innovator&rdquo;) <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> that first became commercially available in 1999 for the treatment of RA. CT-P13 has an identical amino acid sequence to infliximab and is produced in the same type of cell line; it exhibits highly similar in vitro and in vivo pharmacodynamics, binding specificities and affinities, and other biologic and pharmacologic characteristics [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/29,30\" class=\"abstract_t\">29,30</a>].</p><p>CT-P13 has shown equivalent clinical efficacy to the innovator <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> in a small number of randomized clinical trials, including the PLANETRA (Programme evaluating the autoimmune disease investigational drug CT-P13 in RA patients) trial, a phase 3 trial in patients with RA [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/29\" class=\"abstract_t\">29</a>]. The PLANETRA trial, in which CT-P13 was used in combination with MTX, is described separately. (See <a href=\"topic.htm?path=clinical-trials-of-combination-therapy-in-persistently-active-rheumatoid-arthritis-in-adults#H7056898\" class=\"medical medical_review\">&quot;Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults&quot;, section on 'MTX-infliximab biosimilar'</a>.)</p><p>The worldwide availability of this biosimilar for <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> is limited and will depend upon regulatory requirements in different regions and local patent laws and patent expiration dates [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">ADALIMUMAB</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">Adalimumab</a> is a fully humanized immunoglobulin (Ig)G1 monoclonal antibody that inhibits tumor necrosis factor (TNF). Adalimumab is administered every two weeks by subcutaneous injection.</p><p>Trial name &mdash; The ARMADA trial: A fully human anti-tumor necrosis factor-alpha monoclonal antibody for the treatment of RA in patients taking concomitant <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Twenty-four week trial involving 271 patients assigned to receive <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) (20 <span class=\"nowrap\">mg/week)</span> plus either placebo or 20 mg, 40 mg, or 80 mg of <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> every other week.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with rheumatoid arthritis (RA) who had been on a stable dose of MTX (between 12.5 and 25 <span class=\"nowrap\">mg/week)</span> for at least six months and who failed treatment with at least one but not more than four disease-modifying antirheumatic drugs (DMARDs), excluding MTX. In addition, all patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least six swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least nine tender joints</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; ACR20 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR50, ACR70, Health Assessment Questionnaire (HAQ) score [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/24,25\" class=\"abstract_t\">24,25</a>], and serum C-reactive protein level.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; An ACR20 response at week 24 was achieved by a significantly greater proportion of patients in all three <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> groups compared with MTX and placebo (48, 67, and 66 percent in the 20, 40, and 80 mg groups, respectively, compared with 15 percent in the <span class=\"nowrap\">MTX/placebo</span> group).</p><p/><p class=\"bulletIndent1\">The ACR50 response rates in the <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> groups (32, 55, and 43 percent, respectively) were significantly greater than in the <span class=\"nowrap\">MTX/placebo</span> group (8 percent). The 40 mg adalimumab group appeared to fare better than the 80 mg group, but the comparisons were not statistically significant. Twenty-seven percent of patients in the 40 mg group and 19 percent of those in the 80 mg group achieved ACR70 responses, compared with only 5 percent of the group treated with <span class=\"nowrap\">MTX/placebo</span>.</p><p/><p class=\"bulletIndent1\">A majority of patients in the <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> groups achieved ACR20 responses by the end of week one. Adverse events were not different among the four groups.</p><p/><p>Trial name &mdash; Radiographic, clinical, and functional outcomes of treatment with <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> (a human anti-tumor necrosis factor monoclonal antibody) in patients with active RA receiving concomitant MTX therapy: a randomized, placebo-controlled, 52-week trial [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; A 52-week trial involving 619 patients with active RA despite MTX who were randomized the one of three groups:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Placebo plus MTX (20 <span class=\"nowrap\">mg/week)</span> (n = 200)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">Adalimumab</a> 20 mg every other week plus MTX (n = 212)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">Adalimumab</a> 40 mg every other week plus MTX (n = 207)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with RA who had been on MTX for at least three months and on a stable dose (between 12.5 and 25 <span class=\"nowrap\">mg/week)</span> for at least one month. In addition, all patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least six swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least nine tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Either rheumatoid factor positivity or at least one joint erosion evident on radiographs of the hands and feet</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; Three primary outcome measures were identified:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Inhibition of structural joint damage at week 52, assessed by a modified Sharp score [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/7,12,13\" class=\"abstract_t\">7,12,13</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The ACR20 at week 24 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Physical function as measure by the disability index of the HAQ (the HAQ-DI) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/25\" class=\"abstract_t\">25</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR50 and ACR70.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; At week 52, there was less radiographic progression in the patients receiving either 40 <span class=\"nowrap\">mg/week</span> or 20 <span class=\"nowrap\">mg/week</span> of <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> as compared with <span class=\"nowrap\">MTX/placebo</span> (mean change 0.1, 0.8, and 2.7, respectively).</p><p/><p class=\"bulletIndent1\">At week 24, ACR20 responses were achieved by 63 and 61 percent of patients in the <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> groups, compared with 30 percent of patients in the <span class=\"nowrap\">MTX/placebo</span> group. These responses were maintained at 52 weeks. At week 52, the HAQ-DI scores demonstrated statistically significant improvement in the adalimumab groups compared with <span class=\"nowrap\">MTX/placebo</span>.</p><p/><p class=\"bulletIndent1\">The proportion of patients reporting serious infections was higher among patients receiving <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> (4 percent) than in the <span class=\"nowrap\">MTX/placebo</span> group (0.5 percent).</p><p/><p>Trial name &mdash; The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> plus <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Two-year trial of 799 patients randomized to three groups:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Placebo plus MTX 20 <span class=\"nowrap\">mg/week</span> (n = 268)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">Adalimumab</a> 40 mg every other week alone (n = 274)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">Adalimumab</a> 40 mg every other week plus MTX (n = 257)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with aggressive RA of less than three years&rsquo; duration who had not received MTX treatment previously. The patients&rsquo; RA was considered aggressive because they had at least one joint erosion. All patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least eight swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least 10 tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>An erythrocyte sedimentation rate &gt;27 <span class=\"nowrap\">mm/hour</span> or a serum C-reactive protein level &gt;1.5 <span class=\"nowrap\">mg/dL</span></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Rheumatoid factor positivity or at least one joint erosion</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; Co-primary endpoints at year one were the ACR50 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>) and the mean change from baseline in the modified total Sharp score (mTSS) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR20, ACR70, and ACR90. A major clinical response was defined as an ACR70 for six consecutive months.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; Combination therapy of <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> and MTX was superior to both MTX alone and adalimumab alone in all outcomes measured. At year one, 62 percent of patients receiving combination therapy exhibited an ACR50 response, compared with 46 and 41 percent of those who received MTX or adalimumab monotherapy. Similar superiority of combination therapy was seen in ACR20, ACR70, and ACR90 response rates at one and two years.</p><p/><p class=\"bulletIndent1\">There was significantly less radiographic progression among patients in the combination treatment arm at both year one and year two (mTSS increase 1.3 and 1.9, respectively) than in patients in the MTX arm (mTSS increase 5.7 and 10.4) or in the <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> arm (mTSS increase 3.0 and 5.5). These benefits of initial combination therapy, compared with MTX or adalimumab alone, were maintained in the 50.3 percent of the patients who completed the 10-year follow-up on treatment (increase in mTSS from baseline to year 10 of 4.0, 11.0. and 8.8, respectively) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/36\" class=\"abstract_t\">36</a>]. </p><p/><p class=\"bulletIndent1\">After two years of treatment, 49 percent of patients receiving combination therapy had achieved disease remission as indicated by a DAS28 score of less than 2.6, and 49 percent of those in the combination arm were categorized as having achieved major clinical responses as defined above. Both of these rates were approximately twice those found among patients receiving either monotherapy. The adverse event profiles were comparable in all three groups.</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">GOLIMUMAB</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a> is a human immunoglobulin (Ig)G1 kappa monoclonal antibody specific for human tumor necrosis factor (TNF)-alpha that neutralizes TNF-alpha activity. It is usually administered once monthly by subcutaneous injection but has also been studied using less frequent intravenous infusions.</p><p>Trial name &mdash; <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a> in patients with active rheumatoid arthritis despite treatment with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/37\" class=\"abstract_t\">37</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; One-year trial involving 172 patients on a stable dose of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) (&ge;10 mg weekly) who were randomly assigned to receive 50 or 100 mg of <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> every two or four weeks or to receive placebo. At week 20, the dosing interval for patients receiving golimumab every two weeks was increased to every four weeks, and patients on placebo were begun on <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> infusions (3 <span class=\"nowrap\">mg/kg)</span>. Infliximab treatment was begun with infusions at weeks 20, 22, and 28, followed by maintenance therapy every eight weeks. Patients on a stable dose of nonsteroidal antiinflammatory drugs (NSAIDs) or a glucocorticoid dose equivalent to &le;10 <span class=\"nowrap\">mg/day</span> of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> were allowed to continue these medications.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with active rheumatoid arthritis (RA) for at least three months before screening, despite treatment with MTX (&ge;10 <span class=\"nowrap\">mg/week)</span> for three or more months and use of a stable dose for four or more weeks before receiving study drug. At study entry, patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least six swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least six tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least two of the following: C-reactive protein (CRP) &ge;1.5 <span class=\"nowrap\">mg/dL,</span> erythrocyte sedimentation rate (ESR) &ge;28 <span class=\"nowrap\">mm/hour,</span> and morning stiffness &ge;30 minutes</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; ACR20 at week 16 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; DAS28 [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/26,27\" class=\"abstract_t\">26,27</a>] and ACR-N index of improvement [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/11\" class=\"abstract_t\">11</a>] at week 16; ACR20, ACR50, and ACR70 through week 52 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; An ACR20 response at week 16 was achieved by a significantly greater proportion of patients in the <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> plus MTX groups combined than in the placebo plus MTX group (61 versus 37 percent).</p><p/><p class=\"bulletIndent1\">Significantly greater proportions of patients in the <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> groups achieved ACR50 and ACR70 responses at 16 weeks (30.7 versus 5.7 and 12.4 versus 0 percent, respectively). The ACR-N was significantly higher in the golimumab groups (23.5 versus -2.4). The reduction in the DAS28 in the golimumab groups was significantly greater when calculated using either CRP or ESR (-1.8 versus -0.9 and -2.1 versus -1.0, respectively).</p><p/><p class=\"bulletIndent1\">Serious adverse events through week 20 were reported in 9 percent of patients in the <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> groups and in 6 percent of the placebo-treated patients.</p><p/><p>Trial name &mdash; The GO-FORWARD study: <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a>, a human antibody to TNF-alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; A 52-week randomized trial with an open-label extension up to five years involving 444 patients on a stable dose of MTX (&ge;15 to &le;25 <span class=\"nowrap\">mg/week)</span> who were randomly assigned to <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> (100 or 50 mg every four weeks) plus either MTX or placebo capsules or to MTX plus placebo injections. Patients on a stable dose of NSAIDs or a glucocorticoid dose equivalent to &le;10 mg daily of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> were allowed to continue these medications.</p><p/><p class=\"bulletIndent1\">At week 16, all patients with &lt;20 percent improvement in both tender and swollen joint counts, except those on <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> 100 mg plus MTX, had blinded adjustment of medication dosing. For eligible patients receiving golimumab 50 mg plus MTX, golimumab was increased to 100 mg every four weeks, and MTX was continued. For eligible patients receiving golimumab plus placebo, the stable MTX dose taken by the patient prior to screening was resumed, and golimumab was continued. For eligible patients on MTX alone, golimumab 50 mg every four weeks was started, and MTX was continued.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients who had active RA and who were on MTX (&ge;15 <span class=\"nowrap\">mg/week)</span> for at least three months before screening. Patients were on a stable MTX dose (15 to 25 <span class=\"nowrap\">mg/week)</span> during the four-week period immediately preceding screening. At study entry, patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least four swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least four tender joints</p><p/><p>In addition, patients had at least two of the following:</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CRP &ge;1.5 <span class=\"nowrap\">mg/L</span> or ESR &ge;28 <span class=\"nowrap\">mm/hour</span></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Morning stiffness &ge; 30 minutes</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Bone erosion by radiograph or magnetic resonance imaging</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Positive anticyclic citrullinated peptide antibody or rheumatoid factor</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcomes &ndash; ACR20 at week 14 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>) and Health Assessment Questionnaire disability index (HAQ-DI) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/25\" class=\"abstract_t\">25</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR20 at week 24, ACR50 and ACR70 at weeks 14 and 24, and DAS28 remission.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; An ACR20 response at week 14 was achieved significantly more often in patients on <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> (100 or 50 mg) plus MTX compared with golimumab alone or MTX alone (56 and 55 percent versus 44 and 33 percent, respectively). Similar significant differences were seen in improvement in the HAQ-DI (-0.5 and -0.38 versus -0.13 versus -0.13).</p><p/><p class=\"bulletIndent1\">At week 24, after dose adjustments in eligible patients, higher rates of response were seen in <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> plus MTX treated patients in the ACR20 (60 and 60 percent versus 35 and 28 percent), ACR50 (33 and 37 percent versus 20 versus 14 percent), and ACR70 (15 and 20 percent versus 11 and 5 percent, respectively). Differences between the groups receiving MTX alone and the groups receiving both medications were statistically significant. A significantly higher rate of DAS28 remission was also observed (23 and 20 percent versus 12 and 6 percent). Benefit was sustained at week 52 (ACR20 of 58 and 64 percent versus 45 and 44 percent) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/39\" class=\"abstract_t\">39</a>].</p><p/><p class=\"bulletIndent1\">Serious adverse events through week 16 in patients on <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> (100 or 50 mg) plus MTX, golimumab plus placebo, or MTX plus placebo occurred in 9, 5.6, 3.8, and 2.3 percent of patients, respectively. Serious infections occurred in 5.6, 2.2, 0.8, and 0.8 percent of patients, respectively. Serious adverse events up to week 52 were attributed to the actual treatment received at the time of the event, rather than to the initial treatment to which the patient had been allocated, to account for the patients who underwent early escape at week 16 or crossover at week 24; they occurred in 18.3, 8, 12, and 4.5 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/39\" class=\"abstract_t\">39</a>]. Serious infections occurred in 7, 1.9, 3.8, and 0.8 percent of patients, respectively.</p><p/><p>Trial name &mdash; The GO-BEFORE study: <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a> before employing <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> as the first-line option in the treatment of rheumatoid arthritis of early onset [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/40\" class=\"abstract_t\">40</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; A 52-week randomized trial with an open-label extension up to five years, involving 637 patients naive to MTX, biologic disease-modifying antirheumatic drugs (DMARDs), and cytotoxic agents, who were randomly assigned to one of four groups. In all groups, subcutaneous (SC) injections of <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> or placebo were administered every four weeks, and capsules of MTX or placebo were given orally once weekly. MTX was started at 10 <span class=\"nowrap\">mg/week,</span> and the dose was escalated to 20 <span class=\"nowrap\">mg/week</span>. The four groups were:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Group 1 &ndash; Placebo injection plus MTX capsules</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Group 2 &ndash; <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a> (100 mg) injection plus placebo capsules</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Group 3 &ndash; <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a> (50 mg) injection plus MTX capsules</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Group 4 &ndash; <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a> (100 mg) injection plus MTX capsules</p><p/><p>Patients on a stable dose of NSAIDs or a glucocorticoid dose equivalent to &le;10 mg daily of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> were allowed to continue these medications.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with active RA for at least three months before start of study. At screening and baseline patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least four swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least four tender joints</p><p/><p>In addition, at screening <span class=\"nowrap\">and/or</span> baseline patients had at least two of the following:</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CRP &ge;1.5 <span class=\"nowrap\">mg/L</span> or ESR &ge;28 <span class=\"nowrap\">mm/hour</span></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Morning stiffness &ge;30 minutes</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Bone erosion by radiograph or magnetic resonance imaging</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Positive anticyclic citrullinated peptide antibody or rheumatoid factor</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcomes &ndash; The difference in the ACR50 response at week 24 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>) between groups 3 and 4 combined (combined group) versus group 1, and a pairwise comparison of group 3 or group 4 versus group 1.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR20 at week 24 and DAS28 response at week 24.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; An intent-to-treat analysis of the ACR50 response showed a trend toward a difference between the combined group (<a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> plus MTX) and group 1 (MTX alone) that did not achieve significance (38 versus 29 percent, p = 0.053). Group 2 (golimumab alone) was non-inferior to group 1 (MTX alone) at week 24 (33 versus 29 percent).</p><p/><p class=\"bulletIndent1\">The ACR20 was achieved significantly more often in the combined groups (<a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> plus MTX) compared with the MTX alone group (62 versus 49 percent), as was the DAS28 (using CRP level) good or moderate response (75 versus 61 percent).</p><p/><p class=\"bulletIndent1\">Serious adverse events occurred in groups 1 through 4 in 7, 3, 6, and 6 percent, respectively. Serious infections occurred in 2, 1, 1, and 4 percent, respectively.</p><p/><p>Trial name &mdash; <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a>, a new human anti-tumor necrosis factor-alpha antibody, administered intravenously in patients with active rheumatoid arthritis [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; A 48-week trial involving 643 patients on a stable dose of MTX (15 to 25 <span class=\"nowrap\">mg/week)</span> who were randomly assigned to receive <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> (either 2 or 4 <span class=\"nowrap\">mg/kg)</span> administered intravenously every 12 weeks, with either MTX at their usual dose or placebo. At weeks 16 and 24, patients with less than 20 percent improvement in both the swollen and tender joint counts entered early escape and blinded dose regimen adjustment. The specific dose adjustment depended upon the specific preceding treatment. The maximal dose of golimumab was 4 <span class=\"nowrap\">mg//kg,</span> and the maximal dose of MTX was the patient&rsquo;s stable prescreening MTX dose.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with active RA for at least three months before screening, despite treatment with MTX (15 to 25 <span class=\"nowrap\">mg/week)</span> for three or more months and the use of a stable dose for four or more weeks before receiving study drug. At study entry, patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least four swollen joints</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least four tender joints</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least two of the following: C-reactive protein (CRP) &ge;1.5 <span class=\"nowrap\">mg/dL</span> or erythrocyte sedimentation rate (ESR) &ge;28 <span class=\"nowrap\">mm/hour;</span> morning stiffness &ge;30 minutes; bone erosion by radiography or magnetic resonance imaging; or positive testing for anticyclic citrullinated peptide antibody or rheumatoid factor</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; ACR50 at week 14 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR50 at week 24, ACR20 at week 14 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>), and DAS28-CRP [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/26,27\" class=\"abstract_t\">26,27</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; An ACR50 response at week 14 was achieved by a greater proportion of patients in the <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> plus MTX groups combined than in the placebo plus MTX group, but this difference was not significant (21 versus 13 percent, p = 0.051). The difference between these two groups was significant by week 24 (22 versus 9 percent). Differences between the groups receiving golimumab monotherapy and MTX monotherapy were not significant at either week 14 or 24.</p><p/><p class=\"bulletIndent1\">At week 48, the proportions of patients achieving ACR50 and ACR20 responses were highest among those who received <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> 4 <span class=\"nowrap\">mg/kg</span> plus MTX (48 and 70 percent, respectively). A moderate or good DAS28-CRP response was achieved at week 14 significantly more often in patients receiving golimumab plus MTX or golimumab monotherapy, compared with MTX monotherapy (71 or 63 versus 44 percent), but remained significantly different at week 24 only for golimumab plus MTX (61, 43, and 40 percent, respectively). Patients receiving golimumab together with MTX had a lower rate of antibodies to golimumab than those treated without MTX (3 versus 9 percent).</p><p/><p class=\"bulletIndent1\">Serious adverse events through week 48 were seen more often in patients receiving <a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">golimumab</a> (with or without MTX) compared with placebo plus MTX (10 versus 5 percent), including serious infections (4 versus 2 percent). The rate of any infection was also higher in patients who received golimumab (48 versus 41 percent).</p><p/><p><a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a> may be effective in patients previously treated with one or more TNF inhibitors. (See <a href=\"topic.htm?path=clinical-trials-of-combination-therapy-in-persistently-active-rheumatoid-arthritis-in-adults#H12\" class=\"medical medical_review\">&quot;Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults&quot;, section on 'MTX-golimumab'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">CERTOLIZUMAB PEGOL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=certolizumab-pegol-drug-information\" class=\"drug drug_general\">Certolizumab pegol</a> (CZP) is a human anti-tumor necrosis factor (TNF)-alpha antibody Fab' fragment that is chemically linked to polyethylene glycol. It neutralizes membrane-associated and soluble TNF-alpha. CZP is administered every two weeks by subcutaneous injection, and dosing at four-week intervals can be considered for maintenance therapy.</p><p>Several major clinical trials of CZP have been performed in patients with rheumatoid arthritis (RA) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/42-46\" class=\"abstract_t\">42-46</a>]. The efficacy and relative safety of CZP was shown in a systematic review and meta-analysis of trials involving over 2000 patients who received CZP after an inadequate response to nonbiologic disease-modifying antirheumatic drugs (DMARDs), such as <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX), compared with placebo or placebo plus MTX [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/46\" class=\"abstract_t\">46</a>]. Patients receiving CZP (200 mg) were significantly more likely after six months of therapy to achieve an ACR50 response (risk ratio, RR, 6.0, 95% CI 3.8-9.4) with an absolute benefit of 29 percent (95% CI 25-34 percent). Serious adverse events were more frequent with CZP (odds ratio 2.0, 95% CI 1.2-3.3).</p><p>As examples of the randomized trials, the first of two similar trials of CZP plus MTX is summarized below [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/42,43\" class=\"abstract_t\">42,43</a>]. A trial of CZP monotherapy is also reviewed [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/44\" class=\"abstract_t\">44</a>].</p><p>Trial name &mdash; RAPID 1: RA prevention of structural damage 1 trial [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/42\" class=\"abstract_t\">42</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; One-year trial involving 982 patients on a stable dose of MTX (&ge;10 mg weekly) who were randomly assigned to CZP (400 mg at weeks 0, 2, and 4, followed by either 200 or 400 mg every two weeks) or placebo. Patients who did not achieve an ACR20 response at weeks 12 and 14 were withdrawn from the study at week 16. Patients on a stable dose of nonsteroidal antiinflammatory drugs (NSAIDs) or a glucocorticoid dose equivalent to &le;10 <span class=\"nowrap\">mg/day</span> of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> were allowed to continue these medications.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with active RA despite treatment with MTX for six or more months who were on a stable MTX dose of &ge;10 <span class=\"nowrap\">mg/week</span> for two or more months prior to baseline evaluation. Previous treatment with other DMARDs was permitted, with at least a 28-day washout period prior to baseline. For <a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">leflunomide</a>, a six-month washout period was required unless <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">cholestyramine</a> was used for drug elimination. At study entry, patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least nine tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least nine swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>An erythrocyte sedimentation rate &ge;30 <span class=\"nowrap\">mm/hour</span> or a C-reactive protein &gt;15 <span class=\"nowrap\">mg/L</span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcomes &ndash; ACR20 at week 24 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>) and change from baseline in modified total Sharp score (mTSS) at week 52 [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR50 and ACR70 at week 24, Health Assessment Questionnaire disability index (HAQ-DI) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/25\" class=\"abstract_t\">25</a>] at weeks 24 and 52, and mean change from baseline in the mTSS at week 24.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; ACR20 responder rates at week 24 were significantly higher in patients who received CZP (200 or 400 mg) plus MTX than placebo plus MTX (59 and 61 versus 14 percent). At week 52, mean radiographic progression from baseline (change in mTSS) was significantly lower in the CZP-treated patients (+0.4 and +0.2 versus +2.8).</p><p/><p class=\"bulletIndent1\">Efficacy was evident at week one, by which time CZP-treated patients were more likely to have achieved an ACR20 response (23 and 22 versus 6 percent). At week 24, patients treated with CZP were more likely to achieve an ACR50 (37 and 40 versus 8 percent) or ACR70 (21 and 21 versus 3 percent).</p><p/><p class=\"bulletIndent1\">Significant improvement in physical function was also evident in the CZP-treated patients at week one (HAQ-DI mean change of -13.5 and -10.9 versus -2.4). This improvement was sustained through week 52 (-0.60 and -0.63 versus -0.18).</p><p/><p class=\"bulletIndent1\">The rates of serious adverse events and serious infections in the two CZP plus MTX groups and the placebo plus MTX patients were 15.2, 14.8, and 12.0 per 100 patient-years and 7.3, 5.3, and 2.2 per 100 patient-years, respectively. The most common serious infections were pneumonia, gastroenteritis, urinary tract infections, and tuberculosis. Tuberculosis was seen in five patients from Eastern Europe, but none from North America. These included three patients with negative chest radiographs and positive tuberculin skin tests who had received past BCG vaccination, and one individual who worked in a tuberculosis clinic.</p><p/><p>Trial name &mdash; The FAST4WARD study: Efficacy and safety of <a href=\"topic.htm?path=certolizumab-pegol-drug-information\" class=\"drug drug_general\">certolizumab pegol</a> (four weekly dose in rheumatoid arthritis) [<a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/44\" class=\"abstract_t\">44</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Design &ndash; Randomized 24-week trial of 220 patients allocated to receive subcutaneous injections of either CZP (400 mg every four weeks) or placebo. Patients on a stable dose of NSAIDs or a glucocorticoid dose equivalent to &le;10 mg daily of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> were allowed to continue these medications.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient population &ndash; Patients with RA for at least six months, who had failed at least one DMARD due to lack of efficacy or intolerance. Patients were excluded if they had previously received a TNF-alpha inhibitor. Prior to receiving the first dose of study drug, patients were not allowed to have received a biologic DMARD within six months, any DMARD for the greater of 28 days or five half-lives of the drug, or <a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">leflunomide</a> without <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">cholestyramine</a> administration and a further 28-day washout.</p><p/><p class=\"bulletIndent1\">At study entry, patients had:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least nine swollen joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least nine tender joints</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At least one of the following: C-reactive protein (CRP) &ge;10 <span class=\"nowrap\">mg/L,</span> erythrocyte sedimentation rate (ESR) &ge;28 <span class=\"nowrap\">mm/hour,</span> and morning stiffness &ge;45 minutes</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary outcome &ndash; ACR20 response at week 24 (<a href=\"image.htm?imageKey=RHEUM%2F64036\" class=\"graphic graphic_table graphicRef64036 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important secondary outcomes &ndash; ACR50 and ACR70 at week 24, HAQ-DI, patient-reported pain, and health-related quality of life.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major results &ndash; The proportion of patients achieving an ACR20 response was significantly greater with CZP at week 24 (46 versus 9 percent with placebo). Significant differences for ACR20 responses between CZP and placebo were evident after one week of therapy. CZP-treated patients were more likely to achieve ACR50 and ACR70 responses at week 24 (23 versus 4 and 6 versus 0 percent, respectively). Improvements were seen in all components of the ACR core measures set.</p><p/><p class=\"bulletIndent1\">Physical function was significantly improved by week one (HAQ-DI of -0.23 versus +0.04) and through week 24 (-0.36 versus +0.13). A significant decrease in arthritis pain from baseline (by visual analog scale) was also noted at week one (-16.7 versus -5.2) and through week 24 (-20.6 versus +1.7). Significant improvements were also seen in disease activity heath-related quality of life and fatigue.</p><p/><p class=\"bulletIndent1\">Serious adverse events and serious infections in patients on CZP and those on placebo were seen in 7.2 versus 2.8 and 1.8 versus 0 percent, respectively.</p><p/><p class=\"headingAnchor\" id=\"H13023298\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A series of biologic agents that inhibit tumor necrosis factor (TNF)-alpha are available for use in the treatment of rheumatoid arthritis (RA) and several other disorders. The medications all improve the signs and symptoms of rheumatoid arthritis and reduce joint damage. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H2\" class=\"local\">'Overview'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept</a> is a recombinant fusion protein that consists of the soluble TNF receptor (p75) linked to the Fc portion of human immunoglobulin (Ig)G1 (TNFR:Fc). Etanercept is administered by subcutaneous injection once or twice weekly. Etanercept has proven effective in RA when used together with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) or as monotherapy as the initial disease-modifying antirheumatic drug (DMARD) or in patients who have not responded adequately to prior DMARD therapy. (See <a href=\"#H3\" class=\"local\">'Etanercept and related agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> is a chimeric <span class=\"nowrap\">(human/murine)</span> IgG1 monoclonal antibody directed against TNF. Infliximab is administered via intravenous infusion, typically at intervals of six to eight weeks following two doses separated by two weeks. It has proven effective when used together with MTX as the initial DMARD or in patients who have not responded adequately to prior DMARD therapy. A biosimilar for infliximab has also been developed. (See <a href=\"#H7057828\" class=\"local\">'Infliximab'</a> above and <a href=\"#H7057834\" class=\"local\">'Infliximab biosimilar'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">Adalimumab</a> is a fully humanized IgG1 monoclonal antibody that inhibits TNF. Adalimumab is administered every two weeks by subcutaneous injection. It has proven effective in RA when used together with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) or as monotherapy as the initial DMARD or in patients who have not responded adequately to prior DMARD therapy. (See <a href=\"#H5\" class=\"local\">'Adalimumab'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=golimumab-drug-information\" class=\"drug drug_general\">Golimumab</a> is a human IgG1 kappa monoclonal antibody specific for human TNF-alpha that neutralizes TNF-alpha activity. It is usually administered once monthly by subcutaneous injection, but has also been studied using less frequent intravenous infusions. It has proven effective in RA when used together with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (MTX) or as monotherapy as the initial DMARD or in patients who have not responded adequately to prior DMARD therapy. In a randomized trial, golimumab was effective in some patients previously treated with one or more TNF inhibitors. (See <a href=\"#H6\" class=\"local\">'Golimumab'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=certolizumab-pegol-drug-information\" class=\"drug drug_general\">Certolizumab pegol</a> (CZP) is a human anti-TNF-alpha antibody Fab' fragment that is chemically linked to polyethylene glycol. It neutralizes membrane-associated and soluble TNF-alpha. CZP is administered every two weeks by subcutaneous injection, and dosing at four-week intervals can be considered for maintenance therapy. It has proven effective when used as monotherapy or together with MTX in patients who have not responded adequately to prior DMARD therapy. (See <a href=\"#H7\" class=\"local\">'Certolizumab pegol'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H363785319\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge John Stone, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/1\" class=\"nounderline abstract_t\">Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/2\" class=\"nounderline abstract_t\">Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:675.</a></li><li class=\"breakAll\">World Health Organization. Expert Committee on Biological Standardization.  Guidelines on evaluation of similar biotherapeutic products. Geneva, 2009. http://www.who.int/biologicals/areas/biological_ (Accessed on September 28, 2013).</li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/4\" class=\"nounderline abstract_t\">Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2013; :CD004525.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/5\" class=\"nounderline abstract_t\">Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/6\" class=\"nounderline abstract_t\">Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130:478.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/7\" class=\"nounderline abstract_t\">Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985; 28:1326.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/8\" class=\"nounderline abstract_t\">Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/9\" class=\"nounderline abstract_t\">Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/10\" class=\"nounderline abstract_t\">Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46:1443.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/11\" class=\"nounderline abstract_t\">Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum 2005; 52:1637.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/12\" class=\"nounderline abstract_t\">Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14:706.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/13\" class=\"nounderline abstract_t\">Plant MJ, Saklatvala J, Borg AA, et al. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994; 21:1808.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/14\" class=\"nounderline abstract_t\">van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35:26.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/15\" class=\"nounderline abstract_t\">Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372:375.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/16\" class=\"nounderline abstract_t\">van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1:1036.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/17\" class=\"nounderline abstract_t\">van der Heijde DM. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996; 10:435.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/18\" class=\"nounderline abstract_t\">Lassere M, Boers M, van der Heijde D, et al. Smallest detectable difference in radiological progression. J Rheumatol 1999; 26:731.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/19\" class=\"nounderline abstract_t\">Emery P, Vencovsk&yacute; J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76:51.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/20\" class=\"nounderline abstract_t\">Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/21\" class=\"nounderline abstract_t\">Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/22\" class=\"nounderline abstract_t\">Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/23\" class=\"nounderline abstract_t\">St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/24\" class=\"nounderline abstract_t\">Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/25\" class=\"nounderline abstract_t\">Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9:789.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/26\" class=\"nounderline abstract_t\">van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20:579.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/27\" class=\"nounderline abstract_t\">M&auml;kinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64:1410.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/28\" class=\"nounderline abstract_t\">Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68:823.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/29\" class=\"nounderline abstract_t\">Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72:1613.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/30\" class=\"nounderline abstract_t\">Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72:1605.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/31\" class=\"nounderline abstract_t\">Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013; 72:1589.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/32\" class=\"nounderline abstract_t\">Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/33\" class=\"nounderline abstract_t\">Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:1400.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/34\" class=\"nounderline abstract_t\">Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/35\" class=\"nounderline abstract_t\">van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26:743.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/36\" class=\"nounderline abstract_t\">Keystone EC, Breedveld FC, van der Heijde D, et al. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol 2014; 41:5.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/37\" class=\"nounderline abstract_t\">Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:964.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/38\" class=\"nounderline abstract_t\">Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68:789.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/39\" class=\"nounderline abstract_t\">Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010; 69:1129.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/40\" class=\"nounderline abstract_t\">Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60:2272.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/41\" class=\"nounderline abstract_t\">Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010; 62:917.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/42\" class=\"nounderline abstract_t\">Keystone E, Heijde Dv, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58:3319.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/43\" class=\"nounderline abstract_t\">Smolen J, Landew&eacute; RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68:797.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/44\" class=\"nounderline abstract_t\">Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68:805.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/45\" class=\"nounderline abstract_t\">Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002; 41:1133.</a></li><li><a href=\"https://www.uptodate.com/contents/randomized-clinical-trials-of-tumor-necrosis-factor-inhibitors-in-rheumatoid-arthritis/abstract/46\" class=\"nounderline abstract_t\">Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2011; :CD007649.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7499 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13023298\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">OVERVIEW</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ETANERCEPT AND RELATED AGENTS</a><ul><li><a href=\"#H7065759\" id=\"outline-link-H7065759\">Etanercept</a></li><li><a href=\"#H7065908\" id=\"outline-link-H7065908\">Etanercept biosimilar</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">INFLIXIMAB AND RELATED AGENTS</a><ul><li><a href=\"#H7057828\" id=\"outline-link-H7057828\">Infliximab</a></li><li><a href=\"#H7057834\" id=\"outline-link-H7057834\">Infliximab biosimilar</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">ADALIMUMAB</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">GOLIMUMAB</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">CERTOLIZUMAB PEGOL</a></li><li><a href=\"#H13023298\" id=\"outline-link-H13023298\">SUMMARY</a></li><li><a href=\"#H363785319\" id=\"outline-link-H363785319\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"RHEUM/7499|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=RHEUM/64036\" class=\"graphic graphic_table\">- ACR RA response criteria</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=assessment-of-rheumatoid-arthritis-activity-in-clinical-trials-and-clinical-practice\" class=\"medical medical_review\">Assessment of rheumatoid arthritis activity in clinical trials and clinical practice</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-trials-of-combination-therapy-in-persistently-active-rheumatoid-arthritis-in-adults\" class=\"medical medical_review\">Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-management-of-rheumatoid-arthritis-in-adults\" class=\"medical medical_review\">General principles of management of rheumatoid arthritis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=randomized-clinical-trials-in-rheumatoid-arthritis-of-biologic-agents-that-inhibit-il-1-il-6-and-rankl\" class=\"medical medical_review\">Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=randomized-clinical-trials-of-combinations-of-nonbiologic-dmards-in-rheumatoid-arthritis\" class=\"medical medical_review\">Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rituximab-and-other-b-cell-targeted-therapies-for-rheumatoid-arthritis\" class=\"medical medical_review\">Rituximab and other B cell targeted therapies for rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=t-cell-targeted-therapies-for-rheumatoid-arthritis\" class=\"medical medical_review\">T-cell targeted therapies for rheumatoid arthritis</a></li></ul></div></div>","javascript":null}